Chikungunya Vaccine UK: Do You Need It Before You Travel?
If you’re travelling to Sri Lanka, India, parts of Africa, the Caribbean or another area where chikungunya is circulating, you may be wondering whether you need the new chikungunya vaccine.
Chikungunya vaccination at Pierremont Pharmacy:
£179
160
UK cases in 2025
+43%
vs 112 in 2024
75
linked to Sri Lanka
For most travellers, the answer isn’t an automatic yes. Your risk depends on where you’re going, how long you’re staying, current outbreaks and your individual health. But chikungunya is becoming increasingly relevant to UK travellers. UK Health Security Agency figures show 160 cases in England, Wales and Northern Ireland during 2025, compared with 112 in 2024. That’s a 43% increase and the highest annual total since 2014.
Chikungunya vaccination is now available in the UK for selected travellers.
Important vaccine safety update — November 2026
On 20 October 2026, the MHRA withdrew the UK marketing authorisation for IXCHIQ, a live attenuated chikungunya vaccine, following reports of serious adverse reactions.
The MHRA concluded that the vaccine’s benefits no longer outweighed its risks. Healthcare professionals must no longer prescribe, supply or administer IXCHIQ.
Vimkunya is now the only chikungunya vaccine authorised and available in the UK. It is a non-live, virus-like particle vaccine licensed for people aged 12 years and over.
The JCVI updated its guidance on 6 November 2026 to reflect this change.
The safety concerns leading to the withdrawal were associated with IXCHIQ, not Vimkunya. The JCVI has not recommended additional restrictions on Vimkunya.
If you’re planning overseas travel, our pharmacist at Pierremont Pharmacy Travel Clinic in Broadstairs can assess your destination, itinerary and medical history and advise whether chikungunya vaccination, or any other travel vaccine, is appropriate.
Chikungunya vaccination at Pierremont Pharmacy: £179
What is chikungunya?
Chikungunya is a viral infection transmitted mainly through the bites of infected Aedes aegypti and Aedes albopictus mosquitoes. These same mosquitoes can also transmit dengue and Zika. An important practical difference from malaria is that Aedes mosquitoes commonly bite during daylight hours, particularly around the early morning and late afternoon. Significantly, the World Health Organisation (WHO) reports that chikungunya has now been identified in more than 110 countries across Asia, Africa, the Americas and Europe.
Why should travellers take chikungunya seriously?
Chikungunya is rarely fatal, but it can be a thoroughly unpleasant illness. The characteristic symptom is severe joint pain, usually accompanied by sudden fever. Other symptoms can include:
- Joint swelling
- Muscle pain
- Headache
- Nausea
- Fatigue
- Skin rash
Symptoms usually appear around 4–8 days after an infected mosquito bite, although the recognised incubation period ranges from approximately 2–12 days. Most people recover, but one feature makes chikungunya particularly significant: the joint pain doesn’t always disappear with the fever.
Chikungunya joint pain can persist
The WHO reports that chikungunya-related joint pain may continue for weeks, months or even years in some people. Occasional eye, heart and neurological complications have also been described. Older people, babies and people with certain underlying medical conditions appear to be at greater risk of severe disease.
Key point
Chikungunya is rarely fatal, but the prolonged joint pain can be debilitating and may persist well beyond the initial infection.
Chikungunya cases in UK travellers are increasing
UKHSA recorded 160 confirmed or probable chikungunya cases during 2025. That compares with:
- 112 cases in 2024
- 45 in 2023
- 31 in 2022
- 17 in 2021.
The 2025 total was the highest annual figure recorded since 2014 and travel history was available for 156 of the 160 cases. The most frequently reported countries were:
| Country | UK chikungunya cases reporting travel there in 2025 |
|---|---|
| Sri Lanka | 75 |
| India | 17 |
| Bangladesh | 16 |
| Mauritius | 10 |
| Somalia | 8 |
| Cuba | 7 |
| Madagascar | 7 |
| Kenya | 6 |
| Indonesia | 4 |
| Thailand | 4 |
(There is an important limitation to these figures because they don't tell us the individual risk of travelling to each country, because UKHSA (the UK Health Security Agency) doesn't collect the number of UK travellers who visited each destination.)
For example, 17 cases associated with India doesn’t mean India was necessarily more dangerous per traveller than a country with six cases. The figures do show, however, that chikungunya is a genuine and increasing infection among returning UK travellers.
Where does chikungunya occur?
Chikungunya occurs predominantly in tropical and subtropical areas of:
- Southern and South-East Asia
- Africa
- Central and South America
- the Caribbean
- Indian Ocean islands
- parts of the Pacific
Local transmission has also occurred in Europe, and the risk can change considerably from year to year because chikungunya often occurs in outbreaks.
So, asking ‘Does chikungunya occur in Thailand?’ isn’t quite enough.
What we need to understand is: ‘What is the current chikungunya risk where I’m going, at the time I’m travelling?’
Current destination-specific travel health advice should therefore be checked close to departure.
Is there a chikungunya vaccine in the UK?
Yes. As of November 2026, Vimkunya is the only chikungunya vaccine authorised and available in the UK.
| Vaccine | Vaccine type | Current UK status |
|---|---|---|
| Vimkunya | Non-replicating virus-like particle vaccine | Authorised for people aged 12 years and over; one dose |
| IXCHIQ | Live attenuated vaccine | UK marketing authorisation withdrawn on 20 October 2026; must not be administered |
The right starting point isn't 'Which vaccine should I buy?' but rather whether your individual travel risk justifies vaccination in the first place.
Why was IXCHIQ withdrawn?
IXCHIQ was originally authorised for adults travelling to areas where chikungunya is circulating.
Although it generated strong immune responses in clinical trials, serious adverse reactions were subsequently reported following its introduction.
These included:
- Chikungunya-like illness following vaccination
- Serious neurological complications, including encephalitis
- Hospitalisations
- Fatal outcomes in some cases
The reported cases occurred predominantly in older adults and people with underlying medical conditions, although serious reactions were also reported in previously healthy individuals.
In February 2026, the MHRA introduced additional restrictions on IXCHIQ, excluding older adults and people with several common chronic medical conditions.
However, following a further review of the available safety evidence, the MHRA concluded in October 2026 that the vaccine’s benefit-risk balance was no longer favourable.
IXCHIQ has therefore been withdrawn from the UK market and must no longer be prescribed, supplied or administered.
Does this withdrawal affect Vimkunya?
No equivalent safety signal has been identified for Vimkunya.
The two vaccines use fundamentally different technologies. IXCHIQ was a live attenuated vaccine, whereas Vimkunya is a non-replicating virus-like particle vaccine.
In its updated advice of 6 November 2026, the JCVI stated that it did not consider additional restrictions on Vimkunya necessary.
This is reassuring, although ongoing monitoring remains important, particularly because Vimkunya is a relatively new vaccine.
What if I have already received IXCHIQ?
The MHRA advises that people who previously received IXCHIQ and experienced no adverse reactions do not need additional vaccination or other specific medical treatment because of the withdrawal.
Anyone who suspects they experienced an adverse reaction should seek medical advice and report it through the MHRA Yellow Card scheme.
Who should consider chikungunya vaccination?
The UK’s Joint Committee on Vaccination and Immunisation, the JCVI, advises that chikungunya vaccination may be considered for:
- travellers visiting regions with an active chikungunya outbreak
- long-term or frequent travellers to regions where chikungunya transmission has occurred during the previous five years
- laboratory staff working with chikungunya virus.
That wording is important. It doesn’t mean everybody going to a country where chikungunya has occurred should automatically be vaccinated. For example, a two-week hotel holiday during a period of very low transmission presents a different risk from spending several months in an area experiencing a substantial outbreak.
Your assessment should therefore take account of:
- your exact destination
- current outbreak activity
- duration of travel
- frequency of travel
- accommodation
- planned activities
- your age
- your medical conditions
- medicines you take
- pregnancy or breastfeeding where relevant
If you live in Broadstairs, Ramsgate, Margate or elsewhere in Thanet, Pierremont Pharmacy’s travel-health service can assess these factors with you.
What is Vimkunya?
Vimkunya is a recombinant chikungunya vaccine containing virus-like particles. These particles resemble parts of the chikungunya virus closely enough to stimulate an immune response, but they don’t replicate and cannot cause chikungunya infection. Vimkunya is licensed for people aged 12 years and over and given as a single intramuscular injection.
How effective is Vimkunya?
This is where the evidence needs to be interpreted carefully. In the pivotal phase 3 study involving people aged 12 to under 65, 97.8% achieved the predefined neutralising-antibody response 21 days after vaccination. At approximately six months, 85.5% remained above that antibody threshold. In adults aged 65 and over, the corresponding antibody response was 87.3% at day 22 and 75.5% at around six months. Those are impressive immune responses, but they aren’t the same as proving that the vaccine prevents 97.8% of clinical chikungunya infections.
The UK product information is explicit that direct clinical efficacy data aren’t currently available for Vimkunya. Protection has instead been inferred using a predefined neutralising-antibody threshold considered likely to predict protection.
So what does 97.8% mean?
It means 97.8% of the younger trial population reached the predefined antibody threshold after vaccination. It does not mean the vaccine has been shown to prevent 97.8% of chikungunya infections in travellers. This distinction is worth understanding when comparing vaccine claims.
Is Vimkunya safe?
Clinical trials have generally shown Vimkunya to be well tolerated.
Commonly reported adverse reactions include:
- Injection-site pain
- Headache
- Fatigue
- Muscle pain
Most reported reactions were mild or moderate and resolved without specific treatment.
Unlike IXCHIQ, Vimkunya does not contain a replicating live chikungunya virus.
However, no vaccine is entirely without risk. Rare adverse reactions may only become apparent after much larger numbers of people have received a vaccine.
The withdrawal of IXCHIQ illustrates why post-marketing safety monitoring is essential and why vaccination decisions should always consider the balance between potential benefits and harms.
The JCVI has not recommended additional restrictions on Vimkunya following the IXCHIQ withdrawal.
How much does the chikungunya vaccine cost?
Vimkunya uses a single-dose primary schedule, so there isn’t normally a multi-dose course for chikungunya vaccination. However, your travel consultation may identify other vaccinations or medicines relevant to your journey.
Pierremont Pharmacy Travel Clinic, Broadstairs
When should I have the vaccine?
The best approach is to arrange travel-health advice several weeks before your trip whenever possible. For Vimkunya, the immune response was measured 21 days after vaccination. IXCHIQ should currently be given at least 30 days before travel. However, if your trip is sooner, it is still worth having a travel-health assessment to discuss the vaccinations, medicines and other precautions that may be suitable for your trip.
Do I still need mosquito repellent if I've been vaccinated?
Absolutely! Vaccination doesn’t replace mosquito-bite prevention. Aedes mosquitoes can transmit:
- chikungunya
- dengue
- Zika
A chikungunya vaccine provides no protection against dengue or Zika. In general, useful precautions include:
- using an effective insect repellent, such as one containing DEET or icaridin/picaridin
- covering exposed skin where practical
- wearing long sleeves and trousers
- using accommodation with effective window and door screening
- using mosquito nets where appropriate
- reducing exposure to mosquito breeding sites such as standing water.
Remember that Aedes mosquitoes often bite during daylight hours and vaccination doesn’t replace bite prevention. Where vaccination is appropriate, think of vaccination and mosquito avoidance as complementary layers of protection.
Is there a treatment for chikungunya?
Frequently asked questions
Most people recover completely and deaths are uncommon. However, chikungunya can cause severe joint pain, and in some people this persists for weeks, months or even years.
Yes. Two vaccines are currently licensed: Vimkunya and IXCHIQ. They differ in vaccine type, age indication and contraindications, so suitability needs to be assessed individually.
Not automatically, although Sri Lanka was associated with 75 of the UKHSA-recorded travel histories in 2025 during a significant outbreak. Whether vaccination is appropriate for your trip depends on current transmission, your itinerary, duration of stay and individual risk factors.
Not every traveller to India requires vaccination. JCVI recommends considering vaccination particularly when there is active transmission or for long-term or frequent travellers to areas where chikungunya has circulated.
Chikungunya transmission has occurred in Thailand, but country-level history alone isn’t enough to determine whether you need vaccination. Current outbreak information, destination within Thailand, length of stay and personal circumstances should all be considered.
Both Vimkunya and IXCHIQ currently use a single-dose primary schedule. The need for routine revaccination or boosters has not yet been established.
The immune response persists beyond the initial vaccination period, but the duration of clinically meaningful protection and the need for boosters are still being established. Current UK product information doesn’t specify a routine booster schedule.
The MHRA advises that people who received IXCHIQ without experiencing adverse reactions do not need any specific action or additional vaccination because of the withdrawal.
Anyone who suspects an adverse reaction should seek medical advice and report it through the Yellow Card scheme.
Potentially, yes. Vimkunya is licensed for people aged 12 years and over, including older adults. IXCHIQ is no longer indicated for people aged 60 or above in the UK.
Potentially, but vaccine choice matters. IXCHIQ is contraindicated in people with diabetes or hypertension, while Vimkunya has a different contraindication and safety profile. An individual clinical assessment is necessary.
Vimkunya is licensed from 12 years of age. IXCHIQ is licensed only for adults aged 18–59.
Pregnancy requires an individual risk-benefit assessment. Whether vaccination should be considered depends on factors including the likelihood of exposure, destination, timing and the specific vaccine, so personalised travel-health advice is appropriate.
No. Chikungunya, dengue and Zika are separate infections, even though some of the same Aedes mosquitoes can transmit them. Mosquito-bite precautions remain important after vaccination.
Our proposed price is £179 for chikungunya vaccination.
The MHRA withdrew IXCHIQ’s UK marketing authorisation on 20 October 2026 following reports of serious adverse reactions, including chikungunya-like illness, neurological complications, hospitalisations and deaths.
The regulator concluded that the vaccine’s benefits no longer outweighed its risks for UK travellers.
Vimkunya remains authorised and available.
So, should you have the chikungunya vaccine?
For some travellers, chikungunya vaccination makes good sense but for many others, it may provide little additional benefit. The purpose of a travel-health consultation isn’t to give everybody every vaccine available. It is to look at your actual personal exposure risk and weigh the benefits of vaccination against its limitations and potential harms.
For chikungunya, that means asking:
- Where are you travelling?
- Is chikungunya currently circulating there?
- How long will you stay?
- Will you travel there repeatedly?
- What type of trip are you taking?
- How old are you?
- Do you have medical conditions that affect vaccine choice?
This produces a much better decision framework than simply looking at a list of countries.
The withdrawal of IXCHIQ reinforces the importance of making vaccination decisions on the basis of current evidence and individual risk rather than assuming that every available vaccine is automatically worthwhile.
Vimkunya remains an authorised option for appropriate travellers aged 12 and over.
Book a travel-health consultation in Broadstairs
If you're planning overseas travel, Pierremont Pharmacy can review your itinerary, vaccination history, medical history and medicines and advise whether the chikungunya vaccine is appropriate for your trip, along with other travel-health precautions.
We serve Broadstairs, Ramsgate, Margate, Thanet and surrounding East Kent.
Sources
- MHRA. IXCHIQ chikungunya vaccine: UK marketing authorisation withdrawn following safety review. 20 October 2026.
- JCVI. Chikungunya vaccine in UK travellers: JCVI advice. Updated 6 November 2026.
- UK Health Security Agency. Travel-associated infections in England, Wales and Northern Ireland: 2025. Updated March 2026.
- NaTHNaC / TravelHealthPro. Chikungunya.
- World Health Organization. Chikungunya.
- Vimkunya Summary of Product Characteristics.
Written by: Graham Philips, BPharm, Dipp Comm Pharm, FRCPharm. GPhC Registered Pharmacist
Clinically reviewed by: Graham Phillips, Dipp Comm Pharm, FRCPharm
GPhC number: 2027398
Last clinically reviewed: 7 November, 2026
Travel-health recommendations, vaccine availability and disease outbreaks can change. This article provides general information and doesn’t replace an individual travel-health assessment.